Association of programmed death-ligand 1 (PD-L1) and 2 (PD-L2) expression with nivolumab (NIVO) efficacy in advanced melanoma (MEL)

被引：0
|
作者：
Rodig, Scott J.
Gjini, Evisa
Desai, Kaushal
Jin, Chelsea
Horak, Christine
Ruisi, Mary
Weber, Jeffrey
Freeman, Gordon J.
Hodi, F. Stephen
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-CT133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT133
引用
收藏
页数：4
相关论文
共 50 条
  • [1] PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN PHEOCHROMOCYTOMA
    Hashimoto, Yasuhiro
    Imai, Atsushi
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Koie, Takuya
    Ohyama, Chikara
    [J]. JOURNAL OF UROLOGY, 2017, 197 (04): : E474 - E474
  • [2] Programmed death-ligand 1 (PD-L1) expression in pheochromocytoma.
    Hashimoto, Yasuhiro
    Yamamoto, Hayato
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Ohyama, Chikara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [3] Laboratory Programmed death-ligand 2 (PD-L2) expression in bladder cancer
    Yang, Yubo
    Wang, Xiaoming
    Bai, Yunjin
    Feng, Dechao
    Li, Ao
    Tang, Yin
    Wei, Xin
    Han, Ping
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (06) : 603.e9 - 603.e15
  • [4] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN TYPE 2 ENDOMETRIAL CANCER
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1127 - 1127
  • [5] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN TYPE 2 ENDOMETRIAL CANCER
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 220 - 220
  • [6] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN UTERINE CARCINOSARCOMAS
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 219 - 219
  • [7] PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN UTERINE CARCINOSARCOMAS
    Gulec, U. Kucukgoz
    Bagir, E.
    Paydas, S.
    Seydaoglu, G.
    Guzel, A. B.
    Vardar, M. A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1125 - 1125
  • [8] PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
    Long, G. V.
    Larkin, J.
    Ascierto, P. A.
    Hodi, F. S.
    Rutkowski, P.
    Sileni, V.
    Hassel, J.
    Lebbe, C.
    Pavlick, A. C.
    Wagstaff, J.
    Schadendorf, D.
    Dummer, R.
    Hogg, D.
    Haanen, J. B. A. G.
    Corrie, P.
    Hoeller, C.
    Horak, C.
    Wolchok, J.
    Robert, C.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [9] Programmed Death-Ligand 1 (PD-L1) Expression in Pheochromocytoma: Clinicopathologic Correlation
    Xiong, Meng-Jun
    Kissick, Haydn
    Master, Viraj
    Osunkoya, Adeboye O.
    [J]. LABORATORY INVESTIGATION, 2019, 99
  • [10] Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors
    Bedekovics, Judit
    Beke, Livia
    Mokanszki, Attila
    Szilagyi, Szabolcs
    Mehes, Gabor
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (01) : 1 - 9
12345